GlaxoSmithKline Pharmaceuticals (GSK) reported a 5.68% increase in standalone net profit, reaching ₹274.94 crore for the fourth quarter of FY26, compared to the same period last year. Revenue from operations rose by 2.38% to ₹989.15 crore. The company's profit before tax stood at ₹369.12 crore, reflecting a 4% increase from ₹354.9 crore in Q4 FY25. Total expenses saw a slight rise of 0.78% to ₹655.75 crore. Notably, the cost of materials consumed decreased by 6.34%, while employee benefits expenses increased by 7.70%.

GSK's EBITDA for the quarter was ₹347 crore, marking a 5% year-on-year growth and an improved EBITDA margin of 35.1%. The General Medicines portfolio performed well, with leading brands maintaining their market positions. The Vaccines segment also grew, driven by strong demand for pediatric vaccines, particularly Shingrix, which gained traction due to increased awareness of preventive healthcare.

In the Oncology sector, GSK's therapies, including Jemperli and Zejula, showed strong market performance. Jemperli received regulatory approval for treating advanced endometrial cancer, expanding its patient base. The company has also secured market authorization for Blenrep, a therapy for multiple myeloma, which is a significant advancement in cancer treatment. GSK's Managing Director, Bhushan Akshikar, emphasized the company's commitment to innovation and sustainable growth.

Additionally, GSK's board has recommended a final dividend of ₹57 per equity share for the fiscal year ending March 31, 2026, with the record date set for May 29, 2026. If approved at the Annual General Meeting, the dividend will be paid on or after July 1, 2026.